Social Media Ideas for Pierre Fabre

Laboratoires Pierre Fabre appoints Zombré CEO of U.S. Dermocosmetics operations in Secaucus

Laboratoires Pierre Fabre, the world’s second-largest dermo-cosmetics company and one of Europe’s leading pharmaceutical groups, announced Aug. 25 the appointment of Nicolas Zombré...

PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval

A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

<![CDATA[Pharming CEO Fabrice Chouraqui Steps Down Amid Strategic Disagreement with Board]]>

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over f...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Fayuvi]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Derm

Derm Anonymous (not verified) Wed, 10/07/2026 - 04:08 field_thread_url https://cafepharma.com/boards/threads/derm.690595/ board name...

<![CDATA[Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming]]>

<![CDATA[Roundup: GSK Acquires Trispecific T Cell-Engager from Chimagen, Sanofi & Cheplapharm Form Strategic Part...

<![CDATA[Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership]]>

Odyssée

Odyssée is founded upon a philosophy of integrity in our approach to aesthetic medicine. This manifests in evidence-based treatments, a timeless approach rather than following tren...

Puig compra 50% da Isdin à família Esteve por 1.200 milhões de euros

A operação, financiada por capitais próprios e dívida bancária, está dividida em duas tranches. A primeira, no valor de 900 milhões de euros, será paga no primeiro trimestre de 202...

“DURABIO”, a bio-engineering plastic partly made from plant-derived isosorbide, is adopted for ALBION's cosmetic contain...

Mitsubishi Chemical Corporation (Head office: Chiyoda-ku, Tokyo; President and CEO: Manabu Chikumoto) is pleased to announce that the plant-derived bio-engineering plastic DURABIOв...

VERDOT Opens its New Centre of Excellence and Manufacturing Facility in Saint-Beauzire, France

VERDOT, a specialist in purification technologies for the biopharmaceutical industry, strengthens its production capacity with a new site designed to support more sustainable opera...

Aurobindo’s arm, Acrotech Biopharma, launches Adquey in US

The launch marks Acrotech’s entry into the US dermatology market and expands the company’s commercial presence into a new strategic therapeutic area

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...

<![CDATA[Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal]]>

<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>

Pfizer’s eczema drug clears skin in mid-stage trial

Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.

Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions

Pfizer’s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during the European Academy of Dermatology and Venereo...

Viatris’s pipeline strategy: Moving beyond generics to find new growth 

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find new growth. The post Viatris’s pipeline strategy: Movi...

Journey Medical: A Small Pharma With A Large Growth Opportunity